January 30 2004–ALDA Pharmaceuticals Corp. (APH:TSX-V) (the ?Company?) announces that it has granted incentive stock options to purchase an aggregate of 512,353 common shares at an exercise price of $0.20 per share to the directors, officers and certain employees of the Company. The Company has granted further incentive stock options to purchase an aggregate of 40,000 common shares at an exercise price of $0.20 per share to certain consultants of the Company. The options are for a term of two years and expire on January 27, 2006. Options granted to directors, officers and employees of the Company and underlying common shares are subject to a four month hold period from the date of grant in accordance with the policies of the TSX Venture Exchange and applicable securities law. Options granted to consultants of the Company and underlying common shares are subject to a four month hold period from the date of grant in accordance with the policies of the TSX Venture Exchange and a further twelve month hold period in accordance with applicable securities law, pending adoption of the revised Multilateral Instrument 45-102.

Terrance G. Owen, Ph.D., MBA

President, Chief Executive Officer and Director
ALDA Pharmaceuticals Corp.
604-521-8300

terry@aldapharma.com
www.aldapharma.com

About ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. has developed a family of wide spectrum, non-toxic, biodegradable infection control products based on its patent pending T36? technology. Its first product, ViralexTM, has been tested on over 100 infectious bacteria, viruses and fungi. ViralexTM is 100% effective in killing them all within 3 minutes, including HIV, Hepatitis B and TB.

Viralex? has been approved by Health Canada for use as a hospital grade, hard surface disinfectant and by the Canadian Food Inspection Agency for use in restaurants and the food processing industry.

The emergence of SARS, Norwalk Virus and new strains of influenza has increased the market demand for Viralex? as a highly effective, non-toxic and environmentally friendly disinfectant.

January 22 2004–
Portland Oregon based Interstate Meat Dist. Inc. Seeks PR Counsel and Employs Salmon Creek Public Relations Inc. of Vancouver Washington.

It was December 23, the busiest time of the year; the plant was processing at close to capacity and team members were getting ready for the holiday and much deserved time off. The phone rang and a customer reported that BSE-probable (mad cow) beef may have been inspected and approved. Some product was shipped and processed by Interstate Meat Distributor Inc.

Contact: Anita Woodley
Salmon Creek Public Relations Inc.
360-571-5560
awoodley@salmoncreekpr.com

Portland, OR
The first phone call came in from a customer at around 10am, a local radio station reported that beef from the state of Washington was being tested for BSE (mad cow) and some of the beef that had been inspected and approved was shipped to Interstate and one other processor in the Portland area.

Within minutes, the on-site USDA Inspector at Interstate walked into the office of Interstate President, Jerry Meng and confirmed that he was also called by the USDA office in Denver. All products from a shipment on December 12th were under review and a hold order was placed on the product. Interstate began pulling all information related to the shipment. The team at Interstate began informing all customers to pull and hold the product in question. The media was making attempts to inform the public but information was not yet conclusive and Interstate was fielding calls from customers, consumers and media representatives from around the globe. Late the evening of the 23rd, the USDA called and said they were meeting in an emergency recall committee and more information would be available the following morning. While information was inconclusive, one thing was certain: every customer was informed and arrangements were in place to accept returns of all product that was at grocers and other outlets. The number of phone calls was incredible with team members pitching in to answer phones and provide whatever details were available in the early hours of the crisis. It appeared that there was over ten thousand pounds of products that would be re-called. Because of the positive relationships with customers, all customers were told that all returns would be accepted regardless of whether the product was part of the shipment in question or not.

The total returned product jumped to 250,000 pounds and checks totaling hundreds of thousands of dollars were written to customers within forty eight hours of notification of the BSE issue.

On the 24th of December the product in question was being referred to officially as BSE ? Probable. Nevertheless, all Interstate products were being pulled from shelves at grocers throughout the Northwest. It was apparent that lay offs would become necessary.

Interstate has enjoyed a highly regarded reputation built over thirty-five years and there was not a question that the business would go on even with this terrible challenge. But, for Interstate, having a large lay-off of team members was not something they had experienced before. It was right before the holiday and the decision was made to provide extended health benefits and extra pay for team members. Additionally, members were told that they would be called back as soon as possible.

The phones continued to ring but the customers were all cared for and product recalls were proceeding well under the circumstances. It was now members of the media who wanted interviews, opinions and details. This created a challenge for a closely managed family business that was primarily a business to business firm with little experience dealing with a global news story. In addition, there were also concerns and regulations that required the protection of the investigative process and the rights of suppliers and individuals. The USDA suggested that a blanket no comment should be issued regarding all inquiries. Members of the media were suggesting correctly that ?No Comment? may not be in the best interest of Interstate.

Members of the Salmon Creek Public Relations Inc. team were acquainted with the owners of Interstate and keenly aware of the complexities of their situation. As an effort to help, Salmon Creek Public Relations Inc. volunteered to provide whatever support would be needed to help them protect their reputation and provide needed information to representatives of the media. Immediately Interstate requested that Salmon Creek Public Relations Inc. get involved and start fielding questions and providing as much information as possible taking into consideration the directives of the USDA.

Salmon Creek Public Relations Inc. developed a general analysis of the issues and challenges in communications in crisis with a complicated issue like BSE. ?We ascertained the core values and vision of Interstate and we incorporated the culture, vision and values into our strategy for communications?, according to Loran Hickton of Salmon Creek Public Relations Inc.

Salmon Creek met in groups and individually with members of the Interstate team to better understand the effects this crisis had on the company and the individual team members.

Salmon Creek created a series of potential questions that were likely to be asked under the circumstances. Again, meeting in groups and individually to seek accurate responses and to better understand the rationale and philosophy of the company.

Clearly Interstate was not to blame for what had occured. The beef in question was inspected and approved by the USDA at two facilities before arriving at Interstate.

We agreed that we should not communicate regarding how BSE product got into the system, but rather support the process of communications and investigation underway by the USDA.

We quickly implemented standards for speaking to members of the media and consumers. All inquires were provided with USDA web-sites, documents, press releases and phone numbers. All information was factual and documented and we provided no speculation or hypothetical opinions. We expressed a willingness to work with any and all individuals that had an interest or concern.
It was stated (and repeated if possible) that ?Interstate made decisions based on scientific evidence, providing optimally healthy, safe and wholesome products?.

The following ?Question & Answer? was also created to anticipate the general questions.

Q: Tell us about Interstate Meat Distributor Inc.

A: Interstate was incorporated in 1967 by Jack Meng. The company has enjoyed consistent growth of 3-8% per year. The company processes ground beef and pork products for patties and sausage. Today Interstate is still family owned and managed by Jack?s two sons serving in leadership and management roles. In addition to second-generation ownership, many team members are second generation or have been employed since the inception of Interstate. There are currently 120 employees of Interstate, though there was a recent lay-off of 40 team members. Interstate hopes to be calling back team members in the coming weeks.

Q: How has the BSE situation affected Interstate?

A: Safety is always first at Interstate. Receiving inspected beef that was potentially BSE positive is still completely unbelievable and totally unacceptable. Even after many days of dealing with the issue, it still makes no sense and is very frustrating. The beef had been inspected and passed by USDA two times prior to our receiving the product.

It placed us in the center of an issue of which we had no control, but the way it was reported in the media did not explain that any company could have received the product.

It damaged our business. It has required that we spend large amounts of time to protect our excellent reputation.

- It has caused lay-offs.
- It has caused a reduction in business.
- We operate a very close group of team members and we try to create a family environment. We have never had to lay off team members due to business reductions before and this has been painful for our team and most importantly to team members without a paycheck.

Interstate has built the company from the ground-up with over 35 years of service. We are very proud of the positive and committed relationships we have built with our customers. The damage that inspected and approved USDA beef came through the system as BSE positive is harmful to the entire industry. For us it means that many good, caring and committed team members lose their jobs through no fault of theirs or the company. We consistently do everything possible to assure the safety and wholesomeness of products. We not only meet requirements, we exceed them!

Q: What actions did you take when notified that BSE meat came through the system?

A: On the 23rd at 2:00PM the USDA provided us with notification that we may have received products that were associated with the BSE recall. The USDA informed us that the USDA was meeting in ?Recall Committee? and we would be informed the following morning as to actions that should be taken.

On the morning of the 24th we were informed by the USDA of the decisions of the Recall Committee. The Recall Committee asked for all information regarding a load of boneless beef that we received on December 12.We immediately provided requested information. Interstate was already communicating with all customers. The USDA stated that we should draft a document to all affected customers requesting return of product in question. We did so immediately.

We are currently working with the USDA on products being returned.

Q: How much beef was involved or sold to through Interstate?   

A:The USDA informed us that the total amount of beef processed at the first stage was 10,410 pounds. For Interstate, that means our stage of processing expanded to 20,000 pounds. The total returned ground beef will be in excess of 250,000 pounds, with a wholesale market value in excess. $300,000.

Q: What has changed at Interstate as a result of this issue?

A: Interstate has always met and exceeded regulations and standards within our industry. We want to assure consumers that Interstate will increase and redouble all efforts to make certain a safe and wholesome food supply. Further, we await proposed additional actions and safeguards by the USDA to make sure our products are as safe as technologically possible as well. We are encouraged by the immediate changes to testing protocol of BSE. This includes ?Test & Hold? which would have avoided this current issue.

Interstate is back to work and business is coming back. In time it appears that full recovery will occur. Customers understand that Interstate had virtually zero opportunity to know the product was BSE because of multiple inspections and approvals by the USDA. Customers understand that the product could have come through any other
provider and the same situation would have occurred. The damage to business caused by this situation has been costly and only time will reflect the entirety of its effects.

About Salmon Creek Public Relations Inc.: Salmon Creek Public Relations is a Portland Oregon / Vancouver Washington based public relations firm specializing in cause-related communication strategies. Media relations, crisis response, marketing, research, branding, and trade negotiations are just a sample of the services we provide. Salmon Creek is a small firm with proven results in animal health & welfare, entertainment and sporting events.

January 28 2004–Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that f HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world?s population.

Scope
Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population

Overview of the limitations surrounding co-morbid management such as recognition of co
infection, high-risk groups and lack of efficacious antivirals

Report Highlights
Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing
the lifespan of this co-morbid population. Effective treatment is currently hampered by
poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines.

Reasons to Purchase
Effectively target this niche sector, through a complete understanding of the prevalence
of the co-morbid population in the seven major markets

Identify the most promising products in the HIV and HBV pipelines, and track how current
players are seeking to optimize their market share

For a complete index of this report click on
http://www.researchandmarkets.com/reports/42806

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute
thousands of major research publications from the world’s leading publishers, consultants
and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com

Colorado Springs, CO May 4, 2004-?A herd of approximately 70 sheep in the Dome Rock Preserve will not have to deal with the deadly effects of lung worm due to the volunteer efforts of students from Pima Medical Institute?s Veterinarian Assistant Program, 370 Printers Parkway in Colorado Springs. The students, under the direction of Kim Parker, PMI?s veterinarian assistant instructor and Tonya Sharp, division supervisor of Teller County?s Division of Wildlife, worked together to put out hay and apple pulp laced with medication to prevent lung worm disease.

Lung worm causes an upper respiratory infection that is contagious and deadly to Bighorn Sheep, as well as domestic sheep and similar types of animals such as goats and deer. The disease is transmitted orally, through fecal matter, as well as nose to nose contact. The Division of Wildlife?s efforts to treat the disease have been successful, however the infectious ailment has wiped out nearly 90 percent of an entire herd of Bighorn sheep in the past.

?In addition to providing a valuable service to the community, our students gained useful knowledge about a different species of animal,? said Karen McGrath, campus director for PMI in Colorado Springs. ?Our program focuses on the treatment of small domestic animals such as dogs and cats, but it also important to gain exposure to wildlife management, especially in a state like Colorado.?

Graduates of the 26.5 credit-hour Veterinary Assistant Program are trained to perform as an entry-level veterinary assistant. Emphasis is placed on small animal techniques. The materials covered include: anatomy/physiology and pharmacology as it applies to animals, assisting in surgery and anesthesia, and medical terminology. Veterinary nursing techniques are covered in depth. Classes are 31 weeks in length and total 720 hours of training. Graduates of this program are granted a certificate. More information about the program is available by calling (719)-482-7462.

PMI is one of the premiere medical vocational institutes in the western United States. The privately owned, accredited school provides students with a well-rounded education embracing theoretical classroom studies, as well as on-site training at medical facilities that mirror the working environment they will pursue after graduation.

PMI has been serving students since 1972, with campuses in: Albuquerque, New Mexico; Mesa, AZ; Chula Vista, CA, Seattle, WA; Las Vegas, NV; as well as Colorado Springs and Denver. Additional information is available at http://www.pmi.edu.

November 4 2003–The autoimmune diseases are receiving increasing attention in the pharmaceutical industry as progress is made in the understanding of immune and inflammatory processes.

It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition.

Rheumatoid arthritis is a chronic syndrome characterized by non-specific, usually symmetrical inflammation of the peripheral joints, manifested by the formation of hypertrophied synovia known as panni. Pannus formation mirrors the destruction of articular and peri-articular structures, with or without generalized manifestations. The condition differs from osteoarthritis not only through the obligatory involvement of the immune system but also because disease onset occurs early on in life, generally between the ages of 20 and 50, although it can begin at any age.

Since the birth of the modern pharmaceutical industry just over 100 years ago with the synthesis of aspirin, non-steroidal aspirin-like anti-inflammatory drugs (NSAIDs) have been the mainstay of the treatment of rheumatoid and other forms of arthritis. It is
generally accepted that NSAIDs relieve the symptoms of arthritis such as pain and swelling without changing the course of underlying disease. There have been considerable efforts to develop drugs which modify disease progress and these have met with variable success. Immunosuppressants such as cyclosporine or anti-metabolite drugs
such as methotrexate are effective but have dose-limiting adverse effects.

During the last few years however, basic research efforts have significantly progressed our understanding of autoimmune disorders such as rheumatoid arthritis. The disease is caused by increased chemotactic and immunostimulatory activity within the joints of sufferers resulting in an influx of inflammatory cell. The presence of activated immune cells increases local levels of cytokines and other inflammatory mediators propagating this process and supporting pannus proliferation and neovasculaturization, cartilage and bone erosion and eventual joint destruction.

Greater understanding of rheumatoid arthritis etiology has given rise to a large number of potential molecular targets for the development of improved therapeutic candidates. LeadDiscovery’s state of the art report, “Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates” provides a comprehensive analysis of current and future molecular targets. Likewise the report evaluates new drug development activity categorizing emerging therapeutics according
to their molecular targets.

Although significant efforts have resulted in the development of the COX2 inhibitors celebrex and vioxx, one of the most exciting developments in themanagement of rheumatoid arthritis has been the introduction of the anti-TNF biopharmaceuticals remicade and enbrel. These drugs represent a real step forward in the development of anti-inflammatory therapies. There is now an increasing number
of inflammatory cytokines which have become targets for therapeutic intervention with biologicals such as monoclonal antibodies or immuno-fusion proteins. There is also encouraging evidence that cytokines can be targeted by orally active medicinal chemicals.
This report offers an analysis of cytokine targets and therapeutics on the market or in development.

The increasing knowledge of the immune system has revealed a number of targets for specific regulation of immune cells and in particular the process of antigen presentation, lymphocyte activation and leukocyte chemotaxis. The disease modifying arthritis drug arava selectively suppresses lymphocyte activation by inhibiting nucleotide synthesis and new drugs with similar mechanisms of action are in development. Methotrexate remains one of the most widely used disease modifying
drugs in rheumatoid arthritis and attempts are being made to discover improved anti-proliferatives that are more specific and better tolerated. Biologicals which block lymphocyte cell surface receptors thereby preventing activation or adhesion, and molecules that limit chemotaxic are also showing encouraging therapeutic activity;
each of these areas is addressed in this report.

Pannus proliferation is a primary feature of rheumatoid arthritis and therefore the development of anti-proliferative agents represents an opportunity for treating this disease. Another strategy for obtaining the same result is the development of anti-angiogenic agents to prevent the vascularization of inflamed joint tissues. There is considerable overlap in this area with drugs being developed to treat
cancer and this report continues with an analysis of approaches that may increase synovial apoptosis or reduce proliferation or angiogenesis.

One of the cardinal manifestations of rheumatoid arthritis is joint destruction. This feature results from the infiltration of various inflammatory cells into the pannus and the progression of synoviocytes into a phenotype that supports matrix destruction. This process involves the release of various proteases and the inhibition of these
enzymes represents a further strategy in the treatment of rheumatoid arthritis. The report therefore concludes with an analysis of matrix metaloproteinases, elastases and cathepsins; how these enzymes contribute to disease progression and how the drug development
sector is targeting these enzymes.

This report therefore overviews each of the major components of rheumatoid arthritis including cytokine production, leukocyte chemotaxis and adhesion, lymphocyte activation, synovial proliferation, angiogenesis and matrix degradation. In this overview we consider almost 50 molecular targets and more than 150 products being developed by nearly 100 companies therefore representing not only a complete analysis of current areas of research activity but also a thorough examination of therapeutic candidates emerging from this activity. In short “Rheumatoid arthritis: Emerging drug
discovery targets and therapeutic candidates” represents a key tool to anyone wishing to select new drug discovery targets or to evaluate drug development activity relating to
rheumatoid arthritis.

For a complete index of this report click on http://www.researchandmarkets.com/reports/39363

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com

September 23, 2004 — The peak season for Lyme disease transmission has passed in most of the United States, but don?t lower your guard yet. Adult blacklegged ticks can be abundant in the fall, and the potential for acquiring Lyme disease exists until cold winter weather sets in. Although immature ticks are more likely to transmit Lyme disease, adults that survive the winter will produce the next generation of these troubling pests. Fall is a good time to take back your yard from blacklegged ticks. Here are some simple steps you can take this fall to reduce tick populations next spring.

1) Raking leaves from lawns and adjacent wooded areas. Published research has demonstrated up to a 75% reduction in tick numbers following removal of leaves.

2) Placing a barrier between a lawn and forested areas. Borders of dry material like gravel or rock are most likely to be effective. This measure has been reported to reduce tick populations an average of 50%.

3) Mowing areas frequented by people. Mowing step reduces moisture at ground level, making it harder for ticks to survive. Although ticks can be found in mowed yards, their numbers tend to be greatly reduced, compared to the number of ticks in nearby woods.

4) Removing trees and shrubs can also reduce moisture in the soil, further disrupting the tick?s habitat. Plantings that tend to discourage feeding by deer may also reduce tick numbers by reducing the number of deer frequenting your yard.

5) Contacting local pest control professional for guidance on host-directed tick control. New methods are available for controlling ticks on mice and deer, which can dramatically reduce tick numbers. One system controls ticks on mice, another controls ticks on deer. When used for several years, these control measures have been reported to reduce tick populations by over 90%.

Fall is a perfect time to put your tick control program in place. Start with these tips, and make your yard a haven for humans, not a habitat for ticks.

This information comes from a new book ?Ticks Off! Controlling Ticks That Transmit Lyme Disease On Your Property? by Patrick Guilfoile, Ph.D. More information about tick control and the book is available at www.tickbook.com or from the publisher, ForSte Press, Inc., P.O. Box 1537, Bemidji, MN 56619; (218) 243-4016. The book is available from www.tickbook.com, Amazon.com, and local booksellers.

Plant City, FL May 29, 2004 — The Fluoroquinolone Toxicity Research Foundation continues to collect post-marketing reports regarding the non-abating nature of the severe and crippling (and at times fatal) adverse drug reactions associated with fluoroquinolone therapy via the Internet. Since one of the first such forums went on line back in 1999, over five years worth of horror stories regarding the damage these drugs can and will do have been forwarded to the FDA. In spite of the overwhelming evidence of such severe and at times fatal adverse reactions, the FDA continues to refuse to take action. In a recent letter received from the FDA, Frances T. Gipson, FACHE Office of Executive Programs Center for Drug Evaluation and Research, states that ??we will weigh all risks and benefits associated with Fluoroquinolone Class Drugs prior to taking any additional action?We will continue to monitor future adverse events reported to us.? To add insult to injury regarding such inaction by the FDA, Gipson also states ??It was also noted that the majority of those adverse events reported are well-known side effects of the Fluoroquinolone class of drugs??

For more than forty years, since the introduction of Nalidixic Acid in 1962, the victims of fluoroquinolone toxicity have been reporting such ?well-known side effects?, only to be denied the medical care they so desperately need as their physicians have routinely failed to recognize, treat and report such events. Peripheral Neuropathy, spontaneous tendon rupture, severe and non abating joint and tendon damage, as well as fatalities resulting from such toxicity, are all known, listed and published adverse drug reactions to these chemotherapeutic agents, commonly referred to as fluoroquinolones or quinolones. Yet the victims continue to be told by their physicians ?it cannot be the drug? and the FDA continues to ?monitor future adverse events.?

We now add yet another such site from the Internet to our never-ending list. This new site, www.fqvictims.org, is the result of numerous victims joining together in an effort to draw media attention to those of us who are left outside the city gates, like lepers to be pitied and ignored. There you will find numerous case histories, posted in the very words of the victims themselves, which describe the horrific suffering they or their loved ones have endured as a direct result of the FDA?s failure to prevent such carnage. You will also find postings regarding those who have forfeited their lives due to the rampant ignorance regarding the adverse reactions associated with these chemotherapeutic agents. Those who continue to doubt the validity of such reports are invited to witness first hand the suffering endured by one such victim as you will find a video of his suffering on this site. Be forewarned this is not for the faint hearted.

In spite of the overwhelming evidence of the non-abating nature of such injuries, the FDA continues to approve new drugs within this class together with new indications for those already on the market. Ignoring the thousands of such reports we have collected over the past five years. 5,276 reports that include 473 associated deaths and 19,792 total reactions can be found within the AERS reports for Levofloxacin. Together with the 4,995 reports which include 480 associated deaths and 20,890 total reactions found within the AERS reports for Ciprofloxacin as well. (Adverse Event Reporting System maintained by the FDA) Yet, Mr. MacCarthy, Vice President of U.S. Medical Science at Bayer?s West Haven facility states ?If you are telling me that someone had these effects and they were persisting, long term, months to years after treatment I would be surprised.? Those within the media who have an interest in interviewing those who ?had these effects and they were persisting, long term, months to years after treatment? are welcomed to visit this new website as well as the other such sites found on the web. Mr. MacCarthy apparently cannot be bothered to take the time to do so.

The recent addition of www.fqvictims.org only emphasizes the fact that such adverse reactions experienced by such victims have shown to be both persistent and non-abating, ?year after year?, contrary to what Mr. MacCarthy has stated publicly. Since 1999, over five years ago, we now have added over five different sites to our list. All dealing with what Mr. MacCarthy continues to claim to have no knowledge of. Perhaps he may wish to read the postings under ?In Fond Memory Of? on the fqvictims site. It has been stated that ?dead men tell no tales? but thanks to the efforts of those involved with bringing this new site on line; they have been given a chance to do exactly that. For you will find post after post detailing the horrendous manner in which such fatalities related to the careless and thoughtless use of these dangerous drugs, have occurred. No doubt Mr. MacCarthy has no knowledge of the permanent nature of such reactions either. Over a thousand documented fatalities, forty thousand severe adverse reactions, four thousand medical journal entries, five new adverse reaction websites, five years worth of post marketing reports, and the FDA continues to state that they intend to ?continue to monitor future adverse events reported to us?. The victims continue to report the carnage, yet no one is listening. Perhaps with this new site, somebody, somewhere, will.

For additional information:
http://www.fqresearch.org

About the Fluoroquinolone Toxicity Research Foundation
The foundation is a non-profit Internet community consisting of those who have suffered irreversible and non-abating injury as a direct result of fluoroquinolone therapy. The foundation is dedicated to presenting the research regarding these issues in the hope of preventing such injury to others and to make such research readily available to those who have shown a prior interest. We strive to present accurate and up to date information to the victims of such scripting abuse so that they may be in a position to receive the medical care such rampant ignorance has denied them. Such documentation is readily available via the forum or the homepage www.fqresearch.org

Contact Information
D Fuller
Director
The Fluoroquinolone Toxicity Research Foundation
http://www.fqresearch.org